ACADEMIA

Doctors Need Solid Understanding of Hereditary Cancer When Prescribing Lynparza for Breast Cancer: Prof.

July 5, 2018
Doctors should adequately understand the impact of heredity and explain it to patients when they prescribe AstraZeneca’s oral PARP inhibitor Lynparza (olaparib), said Akihiro Sakurai, professor of genetic medicine at Sapporo Medical University School of Medicine, on July 3. Lynparza…

To read the full story

ACADEMIA

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…

Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…